UNMATCHED SUPPLY CHAIN SOLUTIONS FOR THE LIFE SCIENCES INDUSTRY

626
Active Clinical Trials
9
Commercial Products
550,000+
Shipments
150+
Countries
Cryoport_Q2_2022_Box 
2022’s Data ManagementTransitionsWebinar

2022’s Data Management Transitions Webinar

Are your advanced therapy supply chains ready for this year’s 4G/LTE data management transition?

  • How will capacity and connectivity challenges impact carrier services and packaging technology providers?
  • How can you guarantee the certainty of global coverage and data fidelity for your cell and gene therapy shipments?
WATCH NOW
Download our ISO 21973 White Paper

Download our ISO 21973 White Paper

A leap forward in standardizing the regenerative medicine supply chain

  • Ensuring full compliance at every step in the transportation process
  • Standardization at scale
  • Mitigating risk in a zero failure environment
LEARN MORE

Upcoming Events View All

AUG29

Animal Health Corridor Summit 2022

Date: August 29-30, 2022
Location: Kansas City, MO

AUG31

Advanced Therapies Europe 2022

Date: August 31 - September 1, 2022
Location: London, United Kingdom

The Latest From Our Blog View All

The Untapped Potential for Cord Blood as Allogeneic Starting Material

 In support of Cord Blood Awareness Month, Cryoport Systems’ partner, Be The Match BioTherapies®, led a webinar focused on the untapped potential and benefits of cord blood for prospective therapies. Cord blood is the blood that is leftover in the umbilical cord and placenta after birth, that contains life-saving stem cells with the potential to treat hematologic disorders in children and adults such as leukemia and lymphoma.  Historically, the umbilical cord was discarded as medical waste, but cord blood has been used for over 30 years as one of the three cell sources for hematopoietic stem cell transplants, along with bone marrow and peripheral blood. 

Cryoport Systems Global Supply Chain Center: Ready for Launch!

We are quickly approaching the Grand Opening of our first two Global Supply Chain Centers in Houston, TX on June 14th and Morris Plains, NJ on June 16th, 2022.

Although we are about to officially open our facilities, we have already received the first doses of a cell therapy from a clinical-stage biopharmaceutical company. The therapy will be used to treat clinical trial patients with advanced B-cell lymphoma and acute myeloid leukemia at clinics across the United States. The photos below shows our team in Morris Plains receiving the material recently.

shipper-cryocart Cryocart2 MicrosoftTeams-image -EDIT-1

Cryoport® is a trademark of Cryoport, Inc. and used with permission by Cryoport Systems, LLC

Exciting News! Cryoport, Inc., our parent company, has expanded its family of companies in continuing to support temperature controlled supply chain solutions for the life sciences industry. Learn More